Conatus Pharmaceuticals said Monday that it would cut its staff by 40 percent and consider a sale or merger after a drug it was testing as a treatment for an increasingly common form of chronic liver disease failed to beat a placebo in a mid-stage clinical trial—the latest letdown in a number of trial failures.
The company is one among many racing to develop a treatment for nonalcoholic steatohepatitis (NASH), a fatty liver disease whose incidence has risen along with obesity, especially in Western countries. The disease, which causes liver inflammation and scarring, can progress to liver failure, which leaves patients… Read more »
UNDERWRITERS AND PARTNERS
